Fate Therapeutics Stock Analysis
| FATE Stock | USD 1.14 0.09 8.57% |
Fate Therapeutics holds a debt-to-equity ratio of 0.193. Fate Therapeutics' financial risk is the risk to Fate Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Fate Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Fate Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Fate Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Fate Therapeutics' stakeholders.
For many companies, including Fate Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Fate Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Fate Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Fate Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Fate Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Fate Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Fate Therapeutics is said to be less leveraged. If creditors hold a majority of Fate Therapeutics' assets, the Company is said to be highly leveraged.
Fate Therapeutics is undervalued with Real Value of 2.03 and Hype Value of 1.12. The main objective of Fate Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Fate Therapeutics is worth, separate from its market price. There are two main types of Fate Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Fate Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Fate Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in poverty. Fate Stock Analysis Notes
About 79.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fate Therapeutics recorded a loss per share of 1.33. The entity had not issued any dividends in recent years. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Fate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 542 people. To learn more about Fate Therapeutics call Scott Wolchko at 858 875 1800 or check out https://www.fatetherapeutics.com.Fate Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Fate Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Fate Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Fate Therapeutics may become a speculative penny stock | |
| Fate Therapeutics had very high historical volatility over the last 90 days | |
| Fate Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 13.63 M. Net Loss for the year was (186.26 M) with loss before overhead, payroll, taxes, and interest of (92.41 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (122.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are owned by institutional investors |
Fate Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 131.5 M.Technical Drivers
As of the 9th of February, Fate Therapeutics shows the Coefficient Of Variation of 4391.38, downside deviation of 4.66, and Mean Deviation of 3.59. Fate Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Fate Therapeutics variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Fate Therapeutics is priced favorably, providing market reflects its regular price of 1.14 per share. Given that Fate Therapeutics is a hitting penny stock territory we advise to closely look at its total risk alpha.Fate Therapeutics Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Fate Therapeutics price series with the more recent values given greater weights.
Fate Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fate Therapeutics Outstanding Bonds
Fate Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fate Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fate bonds can be classified according to their maturity, which is the date when Fate Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Fate Therapeutics Predictive Daily Indicators
Fate Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fate Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Fate Therapeutics Forecast Models
Fate Therapeutics' time-series forecasting models are one of many Fate Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fate Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Fate Therapeutics Bond Ratings
Fate Therapeutics financial ratings play a critical role in determining how much Fate Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Fate Therapeutics' borrowing costs.| Piotroski F Score | 2 | Frail | View |
| Beneish M Score | (1.79) | Possible Manipulator | View |
Fate Therapeutics Debt to Cash Allocation
Many companies such as Fate Therapeutics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Fate Therapeutics currently holds 85.27 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Fate Therapeutics has a current ratio of 6.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Fate Therapeutics' use of debt, we should always consider it together with its cash and equity.Fate Therapeutics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Fate Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Fate Therapeutics, which in turn will lower the firm's financial flexibility.Fate Therapeutics Corporate Bonds Issued
Most Fate bonds can be classified according to their maturity, which is the date when Fate Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Fate Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Fate Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Fate Therapeutics. By using and applying Fate Stock analysis, traders can create a robust methodology for identifying Fate entry and exit points for their positions.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Fate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 542 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Fate Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |